Akers Biosciences Inc (NASDAQ:AKER) was the recipient of a significant growth in short interest in January. As of January 31st, there was short interest totalling 9,287,791 shares, a growth of 911.6% from the January 12th total of 918,119 shares. Based on an average daily trading volume, of 15,501,673 shares, the short-interest ratio is currently 0.6 days. Currently, 43.4% of the shares of the stock are short sold.
Shares of Akers Biosciences (NASDAQ AKER) opened at $0.43 on Monday. The stock has a market cap of $10.99, a PE ratio of -0.72 and a beta of 1.09. Akers Biosciences has a one year low of $0.12 and a one year high of $2.90.
Akers Biosciences (NASDAQ:AKER) last announced its quarterly earnings data on Wednesday, November 15th. The medical instruments supplier reported ($0.13) earnings per share (EPS) for the quarter. The firm had revenue of $0.68 million for the quarter. Akers Biosciences had a negative return on equity of 94.44% and a negative net margin of 134.31%.
ILLEGAL ACTIVITY WARNING: This news story was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://stocknewstimes.com/2018/02/12/akers-biosciences-inc-aker-short-interest-update.html.
Akers Biosciences Company Profile
Akers Biosciences, Inc, together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States and internationally. The companys marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness.
Receive News & Ratings for Akers Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akers Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.